News
GHRS
19.56
+1.56%
0.30
RBC Capital Keeps Their Buy Rating on GH Research (GHRS)
TipRanks · 1d ago
H.C. Wainwright Reaffirms Their Buy Rating on GH Research (GHRS)
TipRanks · 1d ago
Weekly Report: what happened at GHRS last week (1102-1106)?
Weekly Report · 1d ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 5d ago
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission
Seeking Alpha · 11/03 13:41
Usona psilocybin filing has implications for Compass, Definium, says Canaccord
TipRanks · 11/02 20:15
Weekly Report: what happened at GHRS last week (1026-1030)?
Weekly Report · 11/02 09:20
Weekly Report: what happened at GHRS last week (1019-1023)?
Weekly Report · 10/26 09:20
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program
Seeking Alpha · 10/23 15:45
Weekly Report: what happened at GHRS last week (1012-1016)?
Weekly Report · 10/19 09:20
Weekly Report: what happened at GHRS last week (1005-1009)?
Weekly Report · 10/12 09:21
GH Research to Present TRD and Bipolar Trial Data at ECNP 2026
TipRanks · 10/09 11:27
Weekly Report: what happened at GHRS last week (0928-1002)?
Weekly Report · 10/05 09:21
Weekly Report: what happened at GHRS last week (0921-0925)?
Weekly Report · 09/28 09:20
Weekly Report: what happened at GHRS last week (0914-0918)?
Weekly Report · 09/21 09:20
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities
Seeking Alpha · 09/20 13:19
Weekly Report: what happened at GHRS last week (0907-0911)?
Weekly Report · 09/14 09:21
GH Research Plans Investor Meetings at Morgan Stanley Global Healthcare Conference
TipRanks · 09/11 11:28
FDA names acting heads of drug and vaccine units to permanent roles
Seeking Alpha · 09/09 00:25
Weekly Report: what happened at GHRS last week (0831-0904)?
Weekly Report · 09/07 09:19
More
Webull provides a variety of real-time GHRS stock news. You can receive the latest news about Gh Research Plc through multiple platforms. This information may help you make smarter investment decisions.
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.